Labeling Suit Costs Johnson & Johnson $63 Million

By Admin
A tragic reaction to a widely used medication – Childrens Motrin manufactured by Johnson & Johnson – caused a child to develop toxic ep...

A tragic reaction to a widely used medication – Children’s Motrin manufactured by Johnson & Johnson – caused a child to develop toxic epidermal necrolysis, eventually losing her sight and most of her skin in 2003.

Now, a jury has awarded the Massachusetts teenager and her parents a sum of $63 million over claims that the New Jersey-based multinational failed to provide adequate warnings of potential side effects on the medication’s label.

The extremely rare condition is usually caused by a reaction to drugs. Symptoms first include a fever before severely affecting the mucous membranes, leading to peeling skin covering the entire body.

Mystery Illness - Toxic Epidermal Necrolysis

The Jury’s decision reached Wednesday was met with protests from J&J’s McNeil consumer healthcare division and a statement read, “We disagree with today's verdict and are considering additional legal options. The Reckis family has suffered a tragedy and we sympathize deeply with them.” However, the company believes the label contains sufficient information on side effects and the cause of the teen’s conditions “are very rare conditions, and the specific cause is difficult to ascertain.”

The settlement awarded $50 million to the victim and $6.5 million to each of her parents.
 

Share

Featured Articles

Hyfe AI uses acoustic AI in its digital cough monitoring

Hyfe uses acoustic AI in its digital cough monitoring. Dr. Joe Brew, Co-Founder & CEO of Hyfe AI, tells us more about coughing technology post-COVID-19

Siemens: smart finance to help medical technology growth

Penny Pinnock, Business Development Manager at Siemens Financial Services UK, discusses how adopting digital technology can support the healthcare sector

Healthcare Digital news roundup: prostate cancer & AI

This week in Healthcare Digital, we heard from experts in the sector: Trevor Dearing from Illumio, Avenda Health’s Brit Berry-Pusey & Vish Charan of Abbott

Lexica shares post-COVID-19 digital healthcare trends

Digital Healthcare

Medical devices expanding senior healthcare innovation

Medical Devices & Pharma

Abbott’s CRM medical devices can help cardiac arrhythmia

Medical Devices & Pharma